Tibolone, Oral Estrogen-Progestin Therapy Linked to Risk for Heart Disease
By Elana Gotkine HealthDay Reporter
THURSDAY, Dec. 5, 2024 -- Use of tibolone or oral estrogen-progestin therapy is associated with an increased risk for specific cardiovascular diseases, according to a study published online Nov. 27 in The BMJ.
Therese Johansson, from Uppsala University in Sweden, and colleagues examined the effect of contemporary menopausal hormone therapy on the risk for cardiovascular disease according to the route of administration. The nationwide emulated target trial involved 919,614 women aged 50 to 58 years between 2007 and 2020 without hormone therapy use in the previous two years. Women were assigned to one of eight treatment groups.
Overall, 77,512 women were initiators of any menopausal hormone therapy and 842,102 women were noninitiators. The researchers found that tibolone was associated with an increased risk for cardiovascular disease compared with noninitiation (hazard ratio, 1.52) in intention-to-treat analyses. The risk for ischemic heart disease was increased for initiators of tibolone or oral estrogen-progestin therapy (hazard ratios, 1.46 and 1.21, respectively). The risk for venous thromboembolism was increased in association with oral continuous estrogen-progestin therapy, sequential therapy, and estrogen-only therapy (hazard ratios, 1.61, 2.00, and 1.57, respectively). In per-protocol analyses, tibolone was associated with a higher risk for cerebral infarction and myocardial infarction (hazard ratios, 1.97 and 1.94, respectively).
"We found that starting oral combined continuous therapy or tibolone was associated with an increased risk of cardiovascular disease within the first two years of initiation," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Mortality, Sudden Cardiac Death Higher for Male Professional Bodybuilders
THURSDAY, May 22, 2025 -- The risks for death and sudden cardiac death (SCD) are higher for male bodybuilders than amateurs, according to a study published online May 20 in the...
Risk of Poor Cardiovascular Outcomes Up in Aging Patients With Down Syndrome
THURSDAY, May 15, 2025 -- Individuals with Down syndrome are at increased risk of poor cardiovascular outcomes, according to a study published online May 7 in the Journal of...
CVD Mortality Higher in Women Than Men With Immune-Mediated Inflammatory Diseases
TUESDAY, May 13, 2025 -- For patients with immune-mediated inflammatory diseases (IMID), cardiovascular disease (CVD) mortality decreased from 1999 to 2020, but sex disparities...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.